Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Income: 2016-2024

Historic Net Income for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$69.4 million.

  • Akebia Therapeutics' Net Income rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • As of FY2024, Akebia Therapeutics' Net Income stood at -$69.4 million, which was down 33.67% from -$51.9 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Net Income ranged from a high of -$51.9 million in FY2023 and a low of -$384.8 million during FY2020.
  • For the 3-year period, Akebia Therapeutics' Net Income averaged around -$71.9 million, with its median value being -$69.4 million (2024).
  • As far as peak fluctuations go, Akebia Therapeutics' Net Income tumbled by 37.61% in 2020, and later skyrocketed by 66.59% in 2022.
  • Akebia Therapeutics' Net Income (Yearly) stood at -$384.8 million in 2020, then grew by 26.72% to -$282.0 million in 2021, then surged by 66.59% to -$94.2 million in 2022, then soared by 44.89% to -$51.9 million in 2023, then tumbled by 33.67% to -$69.4 million in 2024.